Drugs / mutant p53 peptide pulsed dendritic cell vaccine
mutant p53 peptide pulsed dendritic cell vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00404339 | Sep 2005 → Mar 2011 | head and neck cancer | Robert Ferris | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00019929 | Aug 2000 → Dec 2005 | lung cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00019084 | Feb 1996 → May 2003 | breast cancer, cervical cancer, colorectal cancer, lung cancer +2 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mutant p53 peptide pulsed dendritic cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019929 ↗ |
| Modality | Vaccine | “Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.” NCT00019084 ↗ |
| Route | Intravenous | “receive mutant p53 peptide-pulsed autologous dendritic cells IV over 1-2 minutes weekly for 5 weeks” NCT00019929 ↗ |